Skip to content

MiMedx

US · MDXG #3541 by market cap
3.05 -0.06 -1.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 3.05 -1.94%
After-hours 3.05 0.00%
4.933.053.052026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on MDXG?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -41.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 6.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth A

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 16.1% Better than 77%
Net income CAGR (3Y) 118.3% Better than 96%
Free cash flow CAGR (3Y) 26.7% Better than 72%
Profitability A

How much profit the business keeps from each dollar of sales and capital.

Gross margin 82.6% Better than 92%
Operating margin 15.3% Better than 65%
Net margin 11.6% Better than 64%
Return on equity 21.6% Better than 80%
Return on invested capital 20.0% Better than 90%
Momentum D

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -29.6% Better than 19%
6-month return -15.7% Better than 32%
12-month return (ex latest month) -42.2% Better than 5%
Distance below 52-week high 59.0% Better than 11%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.3x Better than 83%
Debt to assets 5.2% Better than 79%
Interest coverage 58.0x Better than 91%
Free cash flow / net income 150.2% Better than 65%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 129.5% Better than 88%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -4.98%
1M -27.90%
3M -29.07%
6M -19.53%
YTD -54.95%
1Y -53.44%
3Y -57.46%
5Y -60.54%

Key statistics

Price & volume

Prev close
3.11
Open
3.08
Day range
3.03 - 3.14
Avg price
3.07
Volume
2.12M
Turnover
6.50M
Amplitude
3.54%
52-week range
3.03 - 7.45

Valuation

P/E
9.53
P/E (TTM)
-23.46
P/B
2.11
EPS
0.32
Net profit
46.70M
Net assets
211.15M

Share structure

Market cap
445.07M
Float cap
328.06M
Shares out
145.93M
Float shares
107.56M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 1% of range
3.03 7.45

59.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-1.25M net over the window

Short interest

Shares short
8.97M
As of
2026-10-30

Frequently asked questions

What is the current stock price of MiMedx (MDXG)?

MiMedx last traded at 3.05. This page shows a periodic quote snapshot. Check the displayed quote time.

What is MiMedx's market cap?

About 445.07M.

What is the P/E ratio of MiMedx?

The trailing twelve-month P/E is -23.46. The Valuation tab shows it against the stock's own five-year range.

Does MiMedx pay a dividend?

MiMedx does not currently pay a regular dividend.

Is MiMedx a buy according to analysts?

The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 7.00, which implies 129.5% upside from the current price. This is not investment advice.

What is MiMedx's StockVane Quant Rating?

The StockVane Momentum strategy currently rates MiMedx a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 20:02:27 · For reference only, not investment advice and not tailored to your situation.

MiMedx discussion 0 comments

Add a comment